Repair of double-strand breaks induced by CRISPR-Cas9 leads to large deletions and complex rearrangements

Nature Biotechnology
Michael KosickiAllan Bradley

Abstract

CRISPR-Cas9 is poised to become the gene editing tool of choice in clinical contexts. Thus far, exploration of Cas9-induced genetic alterations has been limited to the immediate vicinity of the target site and distal off-target sequences, leading to the conclusion that CRISPR-Cas9 was reasonably specific. Here we report significant on-target mutagenesis, such as large deletions and more complex genomic rearrangements at the targeted sites in mouse embryonic stem cells, mouse hematopoietic progenitors and a human differentiated cell line. Using long-read sequencing and long-range PCR genotyping, we show that DNA breaks introduced by single-guide RNA/Cas9 frequently resolved into deletions extending over many kilobases. Furthermore, lesions distal to the cut site and crossover events were identified. The observed genomic damage in mitotically active cells caused by CRISPR-Cas9 editing may have pathogenic consequences.

References

Jan 17, 2003·The New England Journal of Medicine·Salima Hacein-Bey-AbinaAlain Fischer
Jun 16, 2009·Nature Methods·Stephen J PettittWilliam C Skarnes
Jan 6, 2011·Proceedings of the National Academy of Sciences of the United States of America·Kosuke YusaNancy L Craig
Jun 25, 2013·Nature Biotechnology·Yanfang FuJeffry D Sander
Jul 23, 2013·Nature Biotechnology·Patrick D HsuFeng Zhang
Apr 29, 2014·Nature Biotechnology·Shengdar Q TsaiJ Keith Joung
Aug 28, 2014·Developmental Dynamics : an Official Publication of the American Association of Anatomists·Jonathon T HillH Joseph Yost
Sep 30, 2014·Cell·Randall J PlattFeng Zhang
Nov 8, 2014·Genesis : the Journal of Genetics and Development·E-Pien TanAllan Bradley
Dec 17, 2014·Nature Biotechnology·Richard L FrockFrederick W Alt
Dec 17, 2014·Nature Biotechnology·Shengdar Q TsaiJ Keith Joung
Jun 30, 2015·Nature Biotechnology·Ayal HendelMatthew H Porteus
Sep 1, 2015·Nature Methods·Miguel A Moreno-MateosAntonio J Giraldez
Dec 3, 2015·Science·Ian M SlaymakerFeng Zhang
Jan 9, 2016·Genesis : the Journal of Genetics and Development·Katharina BoroviakAllan Bradley
Aug 9, 2016·Molecular Cell·Megan van OverbeekAndrew P May
Apr 8, 2017·Nature Medicine·Tatjana I CornuToni Cathomen
Jun 1, 2017·Nature Communications·Ha Youn ShinLothar Hennighausen
Oct 11, 2017·Scientific Reports·Katharina BoroviakAllan Bradley

❮ Previous
Next ❯

Citations

Jul 31, 2018·Nature Biotechnology·Hyunji Lee, Jin-Soo Kim
Sep 8, 2018·Advances in Physiology Education·Barry W Fitzgerald
Feb 9, 2019·Human Vaccines & Immunotherapeutics·January Salas-MckeeJoseph A Fraietta
Apr 5, 2019·Molecular Diagnosis & Therapy·Panayiota PapasavvaCarsten W Lederer
May 16, 2019·Nature Medicine·Anna Azvolinsky
Jun 25, 2019·PloS One·Maria Cristina YunesMaria J Hötzel
Aug 1, 2019·Briefings in Functional Genomics·Marcus C S LeeManuel Llinás
Aug 1, 2019·Human Gene Therapy·Hiu Man Grisch-ChanBeat Thöny
Jul 17, 2019·Nature Plants·Yingxiao ZhangYiping Qi
Aug 14, 2019·Xenotransplantation·Nella FisicaroPeter J Cowan
Aug 23, 2019·The CRISPR Journal·Kylie Standage-BeierXiao Wang
Apr 5, 2019·Molecular Diagnosis & Therapy·Petros PatsaliCarsten W Lederer
Sep 19, 2019·Current Protocols in Toxicology·Cherish A TaylorSomshuvra Mukhopadhyay
Aug 14, 2019·Human Mutation·Katherine J WertVinit B Mahajan
Jan 24, 2019·Cellular and Molecular Life Sciences : CMLS·Dmitry KostyushevVladimir Chulanov
Mar 17, 2019·Nature Biotechnology·Donna Dickenson, Marcy Darnovsky
Oct 12, 2018·The AAPS Journal·Brittany E GivensAliasger K Salem
Sep 7, 2018·PLoS Genetics·Kärt TombergDavid Ginsburg
Nov 8, 2018·BMC Genomics·Sven WarrisDick de Ridder
Sep 5, 2019·Transgenic Research·Charles-Etienne DumeauAnton Wutz
Jan 15, 2019·Cancer Cell International·Debarati GhoshSonali Bhattacharjee
Jan 5, 2019·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Ronald A M BuijsenWilleke M C van Roon-Mom
Aug 23, 2019·Phytopathology·Natalia O KalininaMichael E Taliansky
Jan 31, 2019·Journal of Cellular Physiology·Ansar KarimianBahman Yousefi
Nov 18, 2019·Cell Biology and Toxicology·Maximilian Haeussler
Mar 13, 2019·Nature Reviews. Drug Discovery·Marina CavazzanaEmmanuelle Six
May 1, 2019·PLoS Biology·Haoyi Wang, Hui Yang
Dec 21, 2019·The CRISPR Journal·Martin Jínek
Jan 22, 2019·Nature Reviews. Clinical Oncology·Hao YinDaniel G Anderson
Jan 29, 2020·Nature Reviews. Genetics·Molly GasperiniJay Shendure
Feb 2, 2020·Molecular Neurodegeneration·Tosha WilliamsParamita Chakrabarty

❮ Previous
Next ❯

Related Concepts

Related Feeds

CRISPR Ribonucleases Deactivation

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on mechanisms that underlie deactivation of CRISPR ribonucleases. Here is the latest research.

CRISPR (general)

Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). CRISPR-Cas system enables the editing of genes to create or correct mutations. Discover the latest research on CRISPR here.

CRISPR for Genome Editing

Genome editing technologies enable the editing of genes to create or correct mutations. Clustered regularly interspaced short palindromic repeats (CRISPR) are DNA sequences in the genome that are recognized and cleaved by CRISPR-associated proteins (Cas). Here is the latest research on the use of CRISPR-Cas system in gene editing.